FDA Approves Wellcovorin for Cerebral Folate Transport Deficiency: First Treatment Available

Cerebral folate transport deficiency is a rare neurological condition caused by a genetic variant in the folate receptor 1 gene (FOLR1), which impairs the transport of folate, an essential vitamin for brain health, into the central nervous system. Patients with CFD often experience severe developmental delays, movement disorders, seizures, and other neurological complications, significantly impacting their quality of life. Current treatment options are limited, and the condition has historically been underdiagnosed and poorly understood. The approval of Wellcovorin provides a much-needed therapeutic option, as it has shown promise in improving symptoms associated with this deficiency. The FDA's decision was based on a systematic review of existing literature, including case reports and mechanistic studies that demonstrated the clinical benefits of leucovorin in this population.